Business Wire

AWS and HUMAIN Expand Partnership with NVIDIA AI Infrastructure and AWS AI Chip Deal to Drive Global AI Innovation

19.11.2025 19:38:00 CET | Business Wire | Press Release

Share

Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, a Public Investment Fund (PIF) company delivering global full-stack AI solutions, announced today at the U.S.-Saudi Investment Forum their plans to provide, deploy and manage up to 150,000 AI accelerators in a data center facility known as an “AI Zone” in Riyadh. As part of the expanded partnership, AWS will become HUMAIN’s preferred AI partner globally, and the two companies will collaborate to bring AI compute and services from Saudi Arabia to customers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119637708/en/

Tanuja Randery, Managing Director, Europe, Middle East & Africa, AWS and Tareq Amin, CEO of HUMAIN

The first-of-a-kind AI Zone in Saudi Arabia will support cutting-edge AI training and inference workloads with access to the latest NVIDIA GB300 AI infrastructure and AWS’s Trainium AI chips. The infrastructure will support a broad range of compute-intensive AI workloads, including model training and running inference for AI applications. This will enable customers to rapidly move from concept to production while responsibly leveraging NVIDIA infrastructure and AI software seamlessly integrated with AWS infrastructure and services.

This industry-leading, accelerated computing infrastructure—delivered with the security, scale, and reliability required to run AI workloads with confidence—will establish Saudi Arabia’s first AI Zone as among the most modern and innovative in the world.

The AI Zone will support global enterprises and technology innovators and will serve both Saudi Arabia's national AI needs and the rapidly growing global demand for compute. The availability of specialized AWS generative AI services, including Amazon Bedrock, Amazon AgentCore and Amazon SageMaker, will give customers immediate access to leading foundation models through a single platform. Amazon Bedrock abstracts away infrastructure management, enabling customers to access foundation models without needing to select or manage the underlying compute infrastructure.

To enhance the planned AI Zone’s capabilities, HUMAIN will join the AWS Solution Provider Program, enabling customers to access AWS services through a unified platform to accelerate AI adoption across the region and internationally. This milestone advances the strategic partnership between the two companies and the joint plan announced in May 2025 to invest more than $5 billion in AI infrastructure, AWS services, and AI training and talent development in Saudi Arabia.

“This marks a pivotal moment in our commitment to our partnership with HUMAIN,” said Tanuja Randery, Managing Director, Europe, Middle East & Africa, AWS. “By combining HUMAIN's local expertise and investment with AWS AI solutions—including our advanced infrastructure, hardware partnerships with NVIDIA, the transformative AI platform Amazon Bedrock, and AI solutions for business users including Amazon Quick Suite—we're establishing a world-class innovation hub that will serve customers across Saudi Arabia and around the globe. As an AWS Solution Provider, HUMAIN will empower organizations to unlock the full potential of generative AI and drive agentic transformation for businesses and government entities. Together, we're accelerating digital transformation and fueling economic growth—backed by a deep understanding of local needs and global-scale capabilities. This partnership demonstrates our unwavering commitment to investing in both cutting-edge infrastructure and the talent that will define the future of AI in the Kingdom and beyond.”

“The AI Zone represents the beginning of a multi-gigawatt journey for HUMAIN and AWS. From inception, this infrastructure has been engineered to serve both national priorities and the world’s accelerating demand for AI compute,” said Tareq Amin, CEO of HUMAIN. “What truly sets this partnership apart is the scale of our ambition and the innovation in how we work together. Through a groundbreaking commercial model and a shared commitment to global market expansion, we are creating an ecosystem that will shape the future of how AI ideas can be built, deployed, and scaled for the whole world.”

Empowering innovation, accelerating local talent

This AWS and HUMAIN collaboration is designed to accelerate AI adoption and advance the Kingdom of Saudi Arabia’s goal to become a global AI leader.

Beyond infrastructure, AWS and HUMAIN will collaborate to accelerate AI adoption across the public and private sectors, develop advanced Arabic Large Language Models, including “ALLAM,” HUMAIN’s Arabic-first large language model, and create a unified AI agent marketplace for government services.

To build a sustainable, future-ready workforce, AWS will train 100,000 Saudi citizens in cloud computing and generative AI through the Amazon Academy in collaboration with PIF and support a dedicated upskilling initiative to train 10,000 women. These efforts support the preparation of the workforce for an AI-powered economy projected to contribute $130 billion to the nation's GDP by 2030.

About Amazon Web Services

Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 120 Availability Zones within 38 geographic regions, with announced plans for 10 more Availability Zones and three more AWS Regions in Chile, the Kingdom of Saudi Arabia, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

About HUMAIN

HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas: next-generation data centers, hyper-performance infrastructure & cloud platforms, advanced AI Models, including the world’s most advanced Arabic LLMs built in the Arab world, and transformative AI Solutions that combine deep sector insight with real-world execution.

HUMAIN’s end-to-end model serves both public and private sector organizations, unlocking exponential value across all industries, driving transformation and strengthening capabilities through human-AI synergies. With a growing portfolio of sector-specific AI products and a core mission to drive IP leadership and talent supremacy world-wide, HUMAIN is engineered for global competitiveness and national distinction.

www.humain.com

Forward-Looking Statement

This press release contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to uncertainties. HUMAIN undertakes no obligation to update these statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119637708/en/

Contacts

Press contact
Hana Nemec, HUMAIN
pr@humain.com
+966 53 847 7638

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye